Drug Discovery

© Enhanc3D Genomics

How Hazel Jones is charting new horizons in genomics

By Isabel Cameron

Hazel Jones is the CEO at Enhanc3D Genomics. We sat down with her to discuss her leap of faith into 3D genomics, and how she is scaling the business and driving operational change.

© Getty Images

Danaher acquires Abcam shares in deal worth $5.7BN

By Liza Laws

Danaher is to acquire Abcam for $24 per share - a total enterprise value of approximately $5.7 billion representing approximately 40% more than Abcam's undisclosed share prices in May.


Follow us


View more


Featured Suppliers